Maker of spine surgery implants and technology, including screws, cages and navigation/robotics systems.
Maker of spine surgery implants and technology, including screws, cages and navigation/robotics systems.
Earns per spine surgery, selling the implants and the instrument sets and technology around them, and grows by signing surgeons who adopt its full set of tools. It bought the French imaging company EOS imaging in 2021 to supply pre-surgery planning that complements the implants.
Moat: narrow (switching costs, process know-how). Integrated implant-plus-navigation ecosystem builds surgeon workflow lock-in versus standalone implant makers.
Headquarters: Carlsbad, California · Founded: 1990 · Employees: 913
Size Alphatec (ATEC) is a United States Health Care company (Medical Specialties) with a market value of $1.10B, the 2169th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.06 on 18 Nov 2026.
Performance Over six months the shares fell 14.3%, against -4.5% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 15.3% over the last twelve months (peer median +8.3%); the operating margin is -3.0% (peer median 11.6%).
Valuation It trades at 15.1× forward earnings against a peer median of 18.5× (4th cheapest of 12).
Capital Return on invested capital runs 11.7 points below its cost of capital (8.1% WACC).
Credit Alphatec has 1 bond outstanding ($405M).
Short interest Short interest is 9.2% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $840M | $764M | $612M | $482M | $351M |
| Revenue growth | — | +25% | +27% | +37% | — |
| Gross profit | $520M | $454M | $346M | $254M | $192M |
| EBITDA | $58.2M | $24.6M | -$39.6M | -$88.6M | -$77.2M |
| Net income | -$86.9M | -$143M | -$162M | -$187M | -$151M |
| Free cash flow | $3.07M | $2.78M | -$128M | -$159M | -$125M |
| Capital expenditure | $71.8M | $49.6M | $93.1M | $87.0M | $58.3M |
| Total debt | $594M | $596M | $610M | $542M | $396M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alphatec ATEC | $1.10B | -14% | +15% | -3% | 15.1× | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Globus Medical GMED | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ATEC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.0% | -5.1% | lowest of 21 |
| 6-month return | -14.3% | -4.5% | 8th lowest of 20 |
| Distance from 52-week high | -69.7% | -29.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +15.3% | +8.3% | 5th highest of 19 |
| Operating margin | -3.0% | 11.6% | 6th lowest of 20 |
| Forward P/E | 15.1× | 18.5× | 4th cheapest of 12 |
| ROIC minus cost of capital | -11.7 pp | +0.3 pp | 6th lowest of 19 |
| EV / EBITDA | 28.0× | 8.5× | 2nd most expensive of 7 |
| Net debt / EBITDA | 8.8× | -0.8× | most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
Alphatec has 1 bond outstanding with $405M face value.